Evidence map›Paper›PMID 34825006›Full record

ArticleJournal of diabetes research2021

The Effect of Liraglutide on Epicardial Adipose Tissue in Type 2 Diabetes.

Na Zhao, Xiaoying Wang, Yongbo Wang, Junjie Yao, Chunhong Shi, Jianling Du, Ran Bai

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Epicardial adipose tissue in coronary microvascular disease.American heart journal plus : cardiology research and practice · 2026
    Review
  5. Review
  6. Epicardial Adipose Tissue in Duchenne Muscular Dystrophy Cardiomyopathy.Journal of the American Heart Association · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Benefits of GLP-1 Mimetics on Epicardial Adiposity.Current medicinal chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Na ZhaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.ORCID https://orcid.org/0000-0001-9465-1688
Xiaoying WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Yongbo WangDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Junjie YaoDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Chunhong ShiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Jianling DuDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Ran BaiDepartment of Endocrinology and Metabolism, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, China.ORCID https://orcid.org/0000-0002-9107-3381
Dalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the effect of liraglutide on the thickness of epicardial adipose tissue (EAT) in type 2 diabetes mellitus (T2DM) patients with abdominal obesity.

methodsAbdominal obesity T2DM patients with poor glycemic control were collected and treated with liraglutide. The changes of blood glucose, blood lipid, waist circumference, body mass index (BMI), and EAT thickness were compared after 3 months of treatment with liraglutide. Cardiac magnetic resonance imaging (MRI) was used to measure EAT thickness.

resultsAfter 3 months of treatment with liraglutide, glycosylated hemoglobin (HbA

conclusionLiraglutide significantly reduces EAT thickness in T2DM with abdominal obesity, which provides theoretical support for the cardiovascular benefits of liraglutide.

Indexed as

Adipose TissueAdultBiomarkersBlood GlucoseDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansHypoglycemic AgentsIncretinsLipidsLiraglutideMaleMiddle AgedObesity, AbdominalPericardiumBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsIncretinsLipidsLiraglutide

Identifiers

PMID34825006
PMCPMC8610652
OpenAlexW3212887989

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.